We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Ter7.0
Teriparatide Research
Too few graded studies
307 peer-reviewed studies
What the evidence says
Too few graded studies
Teriparatide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1997–2026 with a typical study size of 428 participants.
Based on 307 studies · 47 meta-analyses · 227 RCTs · 2,814 total participants
Confidence
High confidence
By outcome
Bone healthNew vertebral fractures fell from 14% on placebo to ~5% (RR 0.35); nonvertebral fragility fractures roughly halved; spine/femoral-neck BMD gains exceed placebo and bisphosphonates · Over ~18-24 months of daily use (BMD detectable by ~3 months)
Too few graded studies202 studies
Fracture & skeletal outcomes
Too few graded studies44 studies
Safety profile
Too few graded studies8 studies
Steady research
84 studies in the last 5 years · Latest meta-analysis: 2026
199720112026
1Meta-Analysis2026
In plain English: On the basis of these analyses, bisphosphonate therapy did not appear to affect the time to or rate of fracture healing.
Agarwal N et al. · The lancet. Healthy longevity (2026)
On the basis of these analyses, bisphosphonate therapy did not appear to affect the time to or rate of fracture healing.
Teriparatide does not appear to delay healing and might reduce the time to union for osteoporotic fractures, although further prospective evidence is needed.
Heterogeneous reporting and variation in drug agents and doses used limited the comparison of other variables.